KK3A Stock Overview
A late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Cytokinetics, Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$27.40 |
| 52 Week High | US$55.50 |
| 52 Week Low | US$26.20 |
| Beta | 0.81 |
| 1 Month Change | -19.88% |
| 3 Month Change | -37.16% |
| 1 Year Change | -50.18% |
| 3 Year Change | -25.14% |
| 5 Year Change | 40.51% |
| Change since IPO | 12.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| KK3A | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.1% | -0.3% | 0.8% |
| 1Y | -50.2% | -12.7% | 14.6% |
Return vs Industry: KK3A underperformed the German Biotechs industry which returned -12.7% over the past year.
Return vs Market: KK3A underperformed the German Market which returned 14.6% over the past year.
Price Volatility
| KK3A volatility | |
|---|---|
| KK3A Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: KK3A's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: KK3A's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 498 | Robert Blum | www.cytokinetics.com |
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure.
Cytokinetics, Incorporated Fundamentals Summary
| KK3A fundamental statistics | |
|---|---|
| Market cap | €3.32b |
| Earnings (TTM) | -€551.83m |
| Revenue (TTM) | €17.24m |
192.6x
P/S Ratio-6.0x
P/E RatioIs KK3A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KK3A income statement (TTM) | |
|---|---|
| Revenue | US$19.22m |
| Cost of Revenue | US$357.68m |
| Gross Profit | -US$338.46m |
| Other Expenses | US$276.80m |
| Earnings | -US$615.26m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.15 |
| Gross Margin | -1,761.17% |
| Net Profit Margin | -3,201.47% |
| Debt/Equity Ratio | -291.9% |
How did KK3A perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/18 23:31 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cytokinetics, Incorporated is covered by 41 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Carter Gould | Barclays |
| Huidong Wang | Barclays |
| Jason Zemansky | BofA Global Research |